{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:13:13Z","timestamp":1791922393353,"version":"4.3.4"},"reference-count":197,"publisher":"Elsevier","isbn-type":[{"value":"9780323899390","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.ircmb.2021.09.002","type":"book-chapter","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T11:29:48Z","timestamp":1635420588000},"page":"117-162","source":"Crossref","is-referenced-by-count":12,"title":["The JAK2 mutation"],"prefix":"10.1016","member":"78","reference":[{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.002_bb0010","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.pas.0000213338.25111.d3","article-title":"Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation","volume":"31","author":"Aboudola","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"issue":"17","key":"10.1016\/bs.ircmb.2021.09.002_bb0015","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: stem-cell and probable clonal origin of the disease","volume":"295","author":"Adamson","year":"1976","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0020","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.leu.2404104","article-title":"A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma","volume":"20","author":"Adelaide","year":"2006","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/bs.ircmb.2021.09.002_bb0025","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2010-12-327593","article-title":"Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms","volume":"118","author":"Anand","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0035","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2011-02-335042","article-title":"Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms","volume":"118","author":"Anand","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0040","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s002770050007","article-title":"Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment","volume":"79","author":"Andersson","year":"2000","journal-title":"Ann. Hematol."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.002_bb0045","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1128\/MCB.24.11.4955-4967.2004","article-title":"Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity","volume":"24","author":"Argetsinger","year":"2004","journal-title":"Mol. Cell Biol."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0050","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood.V96.10.3310","article-title":"Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia","volume":"96","author":"Axelrad","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.002_bb0055","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00277-010-0920-6","article-title":"Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies","volume":"89","author":"Bacher","year":"2010","journal-title":"Ann. Hematol."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.002_bb0060","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nsmb.2348","article-title":"Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F","volume":"19","author":"Bandaranayake","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0065","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0070","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","article-title":"Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?","volume":"114","author":"Barbui","year":"2009","journal-title":"Blood"},{"issue":"9464","key":"10.1016\/bs.ircmb.2021.09.002_bb0075","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/bs.ircmb.2021.09.002_bb0080","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0085","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2141.2008.07560.x","article-title":"Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones","volume":"144","author":"Beer","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0090","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2005-12-4852","article-title":"Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders","volume":"108","author":"Bellanne-Chantelot","year":"2006","journal-title":"Blood"},{"issue":"9648","key":"10.1016\/bs.ircmb.2021.09.002_bb0095","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(08)61341-0","article-title":"Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome","volume":"372","author":"Bercovich","year":"2008","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.002_bb0100","first-page":"2832","article-title":"Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2","volume":"118","author":"Bersenev","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.002_bb0105","doi-asserted-by":"crossref","first-page":"140","DOI":"10.5581\/1516-8484.20120034","article-title":"Philadelphia-negative chronic myeloproliferative neoplasms","volume":"34","author":"Bittencourt","year":"2012","journal-title":"Rev. Bras. Hematol. Hemoter."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.002_bb0110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1073\/pnas.0307203101","article-title":"Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder","volume":"101","author":"Braun","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"23","key":"10.1016\/bs.ircmb.2021.09.002_bb0115","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617F-positive myeloproliferative disease","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0120","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"issue":"9501","key":"10.1016\/bs.ircmb.2021.09.002_bb0125","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0130","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1365-2141.2005.05683.x","article-title":"The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera","volume":"130","author":"Cario","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0135","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0140","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","article-title":"Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients","volume":"118","author":"Cervantes","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221635","article-title":"A conditional inducible JAK2V617F transgenic mouse model reveals myeloproliferative disease that is reversible upon switching off transgene expression","volume":"14","author":"Chapeau","year":"2019","journal-title":"PLoS One"},{"issue":"42","key":"10.1016\/bs.ircmb.2021.09.002_bb0150","doi-asserted-by":"crossref","first-page":"15190","DOI":"10.1073\/pnas.1401873111","article-title":"JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response","volume":"111","author":"Chen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0155","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2010.10.013","article-title":"Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling","volume":"18","author":"Chen","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0160","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V83.1.99.99","article-title":"Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: studies in an improved serum-free medium","volume":"83","author":"Correa","year":"1994","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.002_bb0165","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00277-009-0899-z","article-title":"A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs","volume":"89","author":"Crisa","year":"2010","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0170","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.semcdb.2008.07.010","article-title":"SOCS regulation of the JAK\/STAT signalling pathway","volume":"19","author":"Croker","year":"2008","journal-title":"Semin. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0175","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/leu.2008.275","article-title":"Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage","volume":"23","author":"da Costa Reis Monte-Mor","year":"2009","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0180","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood.V80.4.891.891","article-title":"Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor","volume":"80","author":"Dai","year":"1992","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.002_bb0185","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1172\/JCI115009","article-title":"Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3","volume":"87","author":"Dai","year":"1991","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0190","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.002_bb0195","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1084\/jem.185.7.1337","article-title":"Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells","volume":"185","author":"Darley","year":"1997","journal-title":"J. Exp. Med."},{"issue":"7265","key":"10.1016\/bs.ircmb.2021.09.002_bb0200","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0205","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2006-03-007146","article-title":"Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis","volume":"109","author":"Delhommeau","year":"2007","journal-title":"Blood"},{"issue":"25","key":"10.1016\/bs.ircmb.2021.09.002_bb0210","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/blood-2013-07-514208","article-title":"Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs","volume":"123","author":"Duek","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0215","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood-2006-10-054940","article-title":"The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera","volume":"110","author":"Dupont","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011157","article-title":"JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors","volume":"5","author":"Dusa","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0225","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2141.1995.tb03391.x","article-title":"Clonal analysis of haemopoietic cells in essential thrombocythaemia","volume":"90","author":"el Kassar","year":"1995","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0230","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3324\/haematol.2008.002352","article-title":"SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases","volume":"94","author":"Elliott","year":"2009","journal-title":"Haematologica"},{"issue":"6636","key":"10.1016\/bs.ircmb.2021.09.002_bb0235","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/43213","article-title":"A new protein containing an SH2 domain that inhibits JAK kinases","volume":"387","author":"Endo","year":"1997","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.002_bb0240","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1128\/MCB.24.11.4968-4978.2004","article-title":"Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling","volume":"24","author":"Feener","year":"2004","journal-title":"Mol. Cell Biol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0245","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/MCB.17.5.2497","article-title":"Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop","volume":"17","author":"Feng","year":"1997","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/bs.ircmb.2021.09.002_bb0250","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fendo.2017.00071","article-title":"The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK-Receptor Interactions","volume":"8","author":"Ferrao","year":"2017","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0255","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V58.5.916.916","article-title":"Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell","volume":"58","author":"Fialkow","year":"1981","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0260","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1128\/MCB.21.10.3547-3557.2001","article-title":"Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation","volume":"21","author":"Frantsve","year":"2001","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052844","article-title":"Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant","volume":"8","author":"Funakoshi-Tago","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0270","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-2141.2008.07552.x","article-title":"Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia","volume":"144","author":"Gaikwad","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0275","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood-2005-10-009514","article-title":"Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells","volume":"108","author":"Garcon","year":"2006","journal-title":"Blood"},{"issue":"13","key":"10.1016\/bs.ircmb.2021.09.002_bb0280","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-05-431791","article-title":"JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone","volume":"120","author":"Godfrey","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0285","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3324\/haematol.2012.079129","article-title":"Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia","volume":"98","author":"Godfrey","year":"2013","journal-title":"Haematologica"},{"issue":"47","key":"10.1016\/bs.ircmb.2021.09.002_bb0290","doi-asserted-by":"crossref","first-page":"32334","DOI":"10.1074\/jbc.M803813200","article-title":"Effects of the JAK2 inhibitor, AZ960, on Pim\/BAD\/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2","volume":"283","author":"Gozgit","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/bs.ircmb.2021.09.002_bb0295","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0300","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/gcc.20235","article-title":"A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia","volume":"44","author":"Griesinger","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0305","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2141.2009.07870.x","article-title":"Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms","volume":"147","author":"Grimwade","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.002_bb0310","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/sj.leu.2404419","article-title":"Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera","volume":"20","author":"Grunebach","year":"2006","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0315","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1582-4934.2010.01018.x","article-title":"Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases","volume":"14","author":"Haan","year":"2010","journal-title":"J. Cell. Mol. Med."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0320","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood-2006-01-029918","article-title":"Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias","volume":"109","author":"Harir","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.002_bb0325","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V93.2.417","article-title":"A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications","volume":"93","author":"Harrison","year":"1999","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.002_bb0330","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/leu.2013.303","article-title":"Use of the 46\/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNalpha treatment","volume":"28","author":"Hasan","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.002_bb0335","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood-2013-04-498956","article-title":"JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNalpha","volume":"122","author":"Hasan","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.002_bb0340","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/bs.ircmb.2021.09.002_bb0345","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2013-06-501452","article-title":"JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia","volume":"122","author":"Hobbs","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.002_bb0350","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1172\/JCI33010","article-title":"STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice","volume":"117","author":"Huang","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.002_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022148","article-title":"JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients","volume":"6","author":"Irino","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0360","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2006-04-017392","article-title":"Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera","volume":"108","author":"Ishii","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.002_bb0365","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.exphem.2007.07.005","article-title":"Behavior of CD34+ cells isolated from patients with polycythemia vera in NOD\/SCID mice","volume":"35","author":"Ishii","year":"2007","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.002_bb0370","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1182\/blood.V51.2.189.189","article-title":"Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis","volume":"51","author":"Jacobson","year":"1978","journal-title":"Blood"},{"issue":"26","key":"10.1016\/bs.ircmb.2021.09.002_bb0375","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0380","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2008-02-137877","article-title":"The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity","volume":"112","author":"James","year":"2008","journal-title":"Blood"},{"issue":"7037","key":"10.1016\/bs.ircmb.2021.09.002_bb0385","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"16","key":"10.1016\/bs.ircmb.2021.09.002_bb0390","doi-asserted-by":"crossref","first-page":"6224","DOI":"10.1073\/pnas.0601462103","article-title":"The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation","volume":"103","author":"Jamieson","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0395","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s002770050505","article-title":"Development of erythrocytosis in the course of essential thrombocythemia","volume":"78","author":"Jantunen","year":"1999","journal-title":"Ann. Hematol."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.002_bb0400","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1128\/MCB.16.12.6985","article-title":"Direct association with and dephosphorylation of Jak2 kinase by the SH2-domain-containing protein tyrosine phosphatase SHP-1","volume":"16","author":"Jiao","year":"1996","journal-title":"Mol. Cell Biol."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0405","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939430","article-title":"Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia","volume":"32","author":"Johansson","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0410","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.002_bb0415","doi-asserted-by":"crossref","first-page":"4789","DOI":"10.1158\/0008-5472.CAN-10-0610","article-title":"Cbl and human myeloid neoplasms: the Cbl oncogene comes of age","volume":"70","author":"Kales","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.002_bb0420","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.leukres.2007.02.018","article-title":"JAK2 mutations other than V617F: a novel mutation and mini review","volume":"32","author":"Karow","year":"2008","journal-title":"Leuk. Res."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.002_bb0425","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.exphem.2008.06.006","article-title":"Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray","volume":"36","author":"Kawamata","year":"2008","journal-title":"Exp. Hematol."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0430","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/sj.leu.2404214","article-title":"Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders","volume":"20","author":"Kiladjian","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0435","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat. Genet."},{"issue":"25","key":"10.1016\/bs.ircmb.2021.09.002_bb0440","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0445","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/0092-8674(95)90351-8","article-title":"Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals","volume":"80","author":"Klingmuller","year":"1995","journal-title":"Cell"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0450","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-03-0744","article-title":"Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders","volume":"102","author":"Kralovics","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0455","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp. Hematol."},{"issue":"17","key":"10.1016\/bs.ircmb.2021.09.002_bb0460","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0465","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","article-title":"Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders","volume":"108","author":"Kralovics","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0470","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"issue":"5341","key":"10.1016\/bs.ircmb.2021.09.002_bb0475","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0480","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","article-title":"Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden","volume":"112","author":"Landgren","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.002_bb0485","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.exphem.2009.09.009","article-title":"Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation","volume":"37","author":"Laubach","year":"2009","journal-title":"Exp. Hematol."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0490","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0495","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0500","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"20","key":"10.1016\/bs.ircmb.2021.09.002_bb0505","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2013-06-510222","article-title":"JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0510","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.002_bb0515","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2007-09-111971","article-title":"Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0520","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2141.1994.tb08300.x","article-title":"Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF","volume":"87","author":"Li","year":"1994","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0525","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1172\/JCI81749","article-title":"Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis","volume":"125","author":"Liu","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.002_bb0530","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","article-title":"JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation","volume":"19","author":"Liu","year":"2011","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0535","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1074\/jbc.M707125200","article-title":"Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F","volume":"283","author":"Lu","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"52","key":"10.1016\/bs.ircmb.2021.09.002_bb0540","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.002_bb0545","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F","volume":"211","author":"Lundberg","year":"2014","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.002_bb0550","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/leu.2013.102","article-title":"A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression","volume":"27","author":"Marty","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0555","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.002_bb0560","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1128\/MCB.01591-05","article-title":"Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor","volume":"26","author":"Mazurkiewicz-Munoz","year":"2006","journal-title":"Mol. Cell Biol."},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.002_bb0565","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","article-title":"Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis","volume":"10","author":"McKerrell","year":"2015","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.002_bb0570","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","article-title":"Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens","volume":"36","author":"Moliterno","year":"2008","journal-title":"Exp. Hematol."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0575","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0580","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood-2012-01-402396","article-title":"Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera","volume":"120","author":"Mullally","year":"2012","journal-title":"Blood"},{"issue":"23","key":"10.1016\/bs.ircmb.2021.09.002_bb0585","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0590","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.leu.2403879","article-title":"PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation","volume":"19","author":"Murati","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0595","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2141.1984.tb01283.x","article-title":"The 'spent' phase of polycythaemia vera: hypersplenism in the absence of myelofibrosis","volume":"56","author":"Najean","year":"1984","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0600","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/leu.2008.306","article-title":"Incidence and diversity of PAX5 fusion genes in childhood acute lymphoblastic leukemia","volume":"23","author":"Nebral","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0605","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0092-8674(00)81168-X","article-title":"Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis","volume":"93","author":"Neubauer","year":"1998","journal-title":"Cell"},{"issue":"35","key":"10.1016\/bs.ircmb.2021.09.002_bb0610","doi-asserted-by":"crossref","first-page":"32704","DOI":"10.1074\/jbc.M103100200","article-title":"TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase\/protein kinase B signaling pathway","volume":"276","author":"Nguyen","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0615","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0620","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.exphem.2006.11.012","article-title":"Polycythemia vera is not initiated by JAK2V617F mutation","volume":"35","author":"Nussenzveig","year":"2007","journal-title":"Exp. Hematol."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0625","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.molimm.2006.11.025","article-title":"Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease","volume":"44","author":"O'Sullivan","year":"2007","journal-title":"Mol. Immunol."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0630","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2010-02-270108","article-title":"Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms","volume":"116","author":"Oh","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0635","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0640","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/leu.2010.163","article-title":"LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0645","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2009.226","article-title":"The JAK2 46\/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0650","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0655","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0092-8674(00)81167-8","article-title":"Jak2 is essential for signaling through a variety of cytokine receptors","volume":"93","author":"Parganas","year":"1998","journal-title":"Cell"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0660","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.002_bb0665","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.002_bb0670","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3324\/haematol.11643","article-title":"The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels","volume":"92","author":"Percy","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0675","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood-2008-01-134114","article-title":"JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders","volume":"112","author":"Plo","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0680","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/gcc.20585","article-title":"Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia","volume":"47","author":"Poitras","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0685","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/jcp.1040890314","article-title":"Human erythroid colony formation in vitro: evidence for clonal origin","volume":"89","author":"Prchal","year":"1976","journal-title":"J. Cell. Physiol."},{"issue":"24","key":"10.1016\/bs.ircmb.2021.09.002_bb0690","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Letter: Bone-marrow responses in polycythemia vera","volume":"290","author":"Prchal","year":"1974","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0695","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.onc.1208032","article-title":"Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors","volume":"24","author":"Reddy","year":"2005","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.002_bb0700","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res."},{"issue":"26","key":"10.1016\/bs.ircmb.2021.09.002_bb0705","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1182\/blood-2010-08-302265","article-title":"Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia","volume":"116","author":"Rinaldi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2021.09.002_bb0710","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2407-11-24","article-title":"Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival","volume":"11","author":"Rubert","year":"2011","journal-title":"BMC Cancer"},{"issue":"26","key":"10.1016\/bs.ircmb.2021.09.002_bb0715","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2014-07-587238","article-title":"The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm","volume":"124","author":"Sangkhae","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0720","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1046\/j.1365-2443.1999.00263.x","article-title":"Cytokine-inducible SH2 protein-3 (CIS3\/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain","volume":"4","author":"Sasaki","year":"1999","journal-title":"Genes Cells"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0725","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ccr.2009.10.009","article-title":"JAK2 gets histone H3 rolling","volume":"16","author":"Sattler","year":"2009","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0730","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood-2009-06-227033","article-title":"Ubiquitination and degradation of the thrombopoietin receptor c-Mpl","volume":"115","author":"Saur","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0735","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood-2008-07-167056","article-title":"Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del20q acts independently and is not one of the predisposing mutations for JAK2-V617F","volume":"113","author":"Schaub","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0740","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood-2009-09-245381","article-title":"Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms","volume":"115","author":"Schaub","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.002_bb0745","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/sj.leu.2404325","article-title":"Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E","volume":"20","author":"Schnittger","year":"2006","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.002_bb0750","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.22063","article-title":"The JAK2 exon 12 mutations: a comprehensive review","volume":"86","author":"Scott","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.002_bb0755","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0760","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.002_bb0765","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nsmb.2849","article-title":"Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase","volume":"21","author":"Shan","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0770","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/bs.ircmb.2021.09.002_bb0775","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1038\/sj.onc.1203522","article-title":"Modulation of STAT signaling by STAT-interacting proteins","volume":"19","author":"Shuai","year":"2000","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0780","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM199802263380902","article-title":"Expression of Bcl-x in erythroid precursors from patients with polycythemia vera","volume":"338","author":"Silva","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.002_bb0785","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1182\/blood.V98.12.3261","article-title":"Ineffective erythropoiesis in Stat5a(-\/-)5b(-\/-) mice due to decreased survival of early erythroblasts","volume":"98","author":"Socolovsky","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0790","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1210\/endo.136.9.7649117","article-title":"Prolactin receptors and JAK2 in islets of Langerhans: an immunohistochemical analysis","volume":"136","author":"Sorenson","year":"1995","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0795","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3324\/haematol.2009.013623","article-title":"High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations","volume":"95","author":"Stegelmann","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0800","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.exphem.2010.09.008","article-title":"Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients","volume":"39","author":"Stein","year":"2011","journal-title":"Exp. Hematol."},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.002_bb0805","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3324\/haematol.2009.014407","article-title":"Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders","volume":"95","author":"Stein","year":"2010","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0810","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1210\/endo.138.4.5089","article-title":"Prolactin regulation of islet-derived INS-1 cells: characteristics and immunocytochemical analysis of STAT5 translocation","volume":"138","author":"Stout","year":"1997","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0815","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3324\/haematol.2010.029678","article-title":"Extent of hematopoietic involvement by TET2 mutations in JAK2V(6)(1)(7)F polycythemia vera","volume":"96","author":"Swierczek","year":"2011","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/bs.ircmb.2021.09.002_bb0820","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/bs.ircmb.2021.09.002_bb0825","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0830","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.002_bb0835","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMc091348","article-title":"Mutation in TET2 in myeloid cancers","volume":"361","author":"Tefferi","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/bs.ircmb.2021.09.002_bb0840","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0002-9343(00)00449-6","article-title":"A clinical update in polycythemia vera and essential thrombocythemia","volume":"109","author":"Tefferi","year":"2000","journal-title":"Am. J. Med."},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0845","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0850","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2007-01-069237","article-title":"Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation","volume":"110","author":"Teofili","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0855","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/bs.ircmb.2021.09.002_bb0860","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0865","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/nsmb.2673","article-title":"Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases","volume":"20","author":"Toms","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0870","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20040762","article-title":"Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis","volume":"200","author":"Tong","year":"2004","journal-title":"J. Exp. Med."},{"issue":"6-7","key":"10.1016\/bs.ircmb.2021.09.002_bb0875","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1051\/medsci\/2005216-7669","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"21","author":"Ugo","year":"2005","journal-title":"Med. Sci. (Paris)"},{"issue":"10","key":"10.1016\/bs.ircmb.2021.09.002_bb0880","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/MCB.22.10.3316-3326.2002","article-title":"Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1","volume":"22","author":"Ungureanu","year":"2002","journal-title":"Mol. Cell Biol."},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0885","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nsmb.2099","article-title":"The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling","volume":"18","author":"Ungureanu","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"21","key":"10.1016\/bs.ircmb.2021.09.002_bb0890","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0895","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood-2008-04-154708","article-title":"The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation","volume":"112","author":"Van Pelt","year":"2008","journal-title":"Blood"},{"issue":"15","key":"10.1016\/bs.ircmb.2021.09.002_bb0900","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2010-06-291310","article-title":"JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma","volume":"117","author":"Van Roosbroeck","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/bs.ircmb.2021.09.002_bb0905","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/bs.ircmb.2021.09.002_bb0910","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nsmb.2807","article-title":"Structural basis of recognition of interferon-alpha receptor by tyrosine kinase 2","volume":"21","author":"Wallweber","year":"2014","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"15","key":"10.1016\/bs.ircmb.2021.09.002_bb0915","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","article-title":"Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice","volume":"119","author":"Walz","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0920","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V95.1.19","article-title":"The Jak-Stat pathway in normal and perturbed hematopoiesis","volume":"95","author":"Ward","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/bs.ircmb.2021.09.002_bb0925","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2007-07-102186","article-title":"The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes","volume":"111","author":"Wernig","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.ircmb.2021.09.002_bb0930","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/bs.ircmb.2021.09.002_bb0935","first-page":"2057","article-title":"Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase","volume":"11","author":"Wilks","year":"1991","journal-title":"Mol. Cell Biol."},{"issue":"14","key":"10.1016\/bs.ircmb.2021.09.002_bb0940","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1182\/blood-2009-03-209544","article-title":"Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells","volume":"115","author":"Will","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0945","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2009-02-206573","article-title":"ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling","volume":"114","author":"Wood","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0950","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2006-03-009472","article-title":"JAK2(V617F): Prevalence in a large Chinese hospital population","volume":"109","author":"Xu","year":"2007","journal-title":"Blood"},{"issue":"15","key":"10.1016\/bs.ircmb.2021.09.002_bb0955","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/blood-2011-03-345215","article-title":"Critical requirement for Stat5 in a mouse model of polycythemia vera","volume":"119","author":"Yan","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.002_bb0960","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1002\/j.1460-2075.1995.tb07281.x","article-title":"A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors","volume":"14","author":"Yoshimura","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/bs.ircmb.2021.09.002_bb0965","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/bs.ircmb.2021.09.002_bb0970","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2005-07-3037","article-title":"Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells","volume":"107","author":"Zeuner","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.ircmb.2021.09.002_bb0975","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1182\/blood-2003-05-1479","article-title":"Role of Ras signaling in erythroid differentiation of mouse fetal liver cells: functional analysis by a flow cytometry-based novel culture system","volume":"102","author":"Zhang","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2021.09.002_bb0980","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2257.2006.00864.x","article-title":"The investigation of JAK2 mutation in Chinese myeloproliferative diseases-identification of a novel C616Y point mutation in a PV patient","volume":"29","author":"Zhang","year":"2007","journal-title":"Int. J. Lab. Hematol."},{"issue":"26","key":"10.1016\/bs.ircmb.2021.09.002_bb0985","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1056\/NEJMoa0804953","article-title":"Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders","volume":"359","author":"Zhao","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/bs.ircmb.2021.09.002_bb0990","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0962-8924(94)90143-0","article-title":"JAK protein tyrosine kinases: their role in cytokine signalling","volume":"4","author":"Ziemiecki","year":"1994","journal-title":"Trends Cell Biol."}],"container-title":["International Review of Cell and Molecular Biology","Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821001064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644821001064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T11:09:29Z","timestamp":1753787369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644821001064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780323899390"],"references-count":197,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2021.09.002","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}